After two decades in the making, scientists have cracked the code on a drug that can repair DNA, setting the scene for a new ...
Investor's Business Daily on MSN
In the 'uber bull' biotech market, is structure the next Metsera?
In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.
Jasmine Cutler does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
CHICAGO — A big breakthrough in cancer research and it’s all due to a tiny structure. The science was developed in Chicago. They took an old drug and made it better. The restructured drug appears to ...
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Scientists discovered a new class of antibiotic that kills bacteria in a unique way and isn't vulnerable to existing drug resistance. When you purchase through links on our site, we may earn an ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback